Pall scores EU market first with prion filter
This article was originally published in Clinica
Executive Summary
Targeting the blood transfusions safety market in Europe, Pall has CE-marked for sale what it claims is the first technology that removes from red cells infectious prions that could cause vCJD (variant Cruetzfeldt-Jakob disease).